• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝缺血再灌注损伤中分子靶点及治疗干预策略的现状和展望。

Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury.

机构信息

School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.

出版信息

Clin Mol Hepatol. 2024 Oct;30(4):585-619. doi: 10.3350/cmh.2024.0222. Epub 2024 Jul 1.

DOI:10.3350/cmh.2024.0222
PMID:38946464
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11540405/
Abstract

Hepatic ischemia‒reperfusion injury (HIRI) is a common and inevitable complication of hepatic trauma, liver resection, or liver transplantation. It contributes to postoperative organ failure or tissue rejection, eventually affecting patient prognosis and overall survival. The pathological mechanism of HIRI is highly complex and has not yet been fully elucidated. The proposed underlying mechanisms include mitochondrial damage, oxidative stress imbalance, abnormal cell death, immune cell hyperactivation, intracellular inflammatory disorders and other complex events. In addition to serious clinical limitations, available antagonistic drugs and specific treatment regimens are still lacking. Therefore, there is an urgent need to not only clarify the exact etiology of HIRI but also reveal the possible reactions and bottlenecks of existing drugs, helping to reduce morbidity and shorten hospitalizations. We analyzed the possible underlying mechanism of HIRI, discussed various outcomes among different animal models and explored neglected potential therapeutic strategies for HIRI treatment. By thoroughly reviewing and analyzing the literature on HIRI, we gained a comprehensive understanding of the current research status in related fields and identified valuable references for future clinical and scientific investigations.

摘要

肝缺血再灌注损伤(HIRI)是肝外伤、肝切除或肝移植后常见且不可避免的并发症。它导致术后器官衰竭或组织排斥,最终影响患者的预后和总体生存率。HIRI 的病理机制非常复杂,尚未完全阐明。提出的潜在机制包括线粒体损伤、氧化应激失衡、异常细胞死亡、免疫细胞过度激活、细胞内炎症紊乱等复杂事件。除了严重的临床局限性外,目前还缺乏拮抗药物和特定的治疗方案。因此,不仅需要阐明 HIRI 的确切病因,还需要揭示现有药物的可能反应和瓶颈,以降低发病率并缩短住院时间。我们分析了 HIRI 的可能潜在机制,讨论了不同动物模型中的各种结果,并探讨了 HIRI 治疗中被忽视的潜在治疗策略。通过对 HIRI 相关文献进行全面审查和分析,我们全面了解了相关领域的研究现状,并为未来的临床和科学研究提供了有价值的参考文献。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33a/11540405/48ba1fdf934c/cmh-2024-0222f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33a/11540405/fe1cd80ee060/cmh-2024-0222f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33a/11540405/458e417d9dad/cmh-2024-0222f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33a/11540405/cd1c348dec7e/cmh-2024-0222f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33a/11540405/5c476f862d3b/cmh-2024-0222f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33a/11540405/9a718fc9f4eb/cmh-2024-0222f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33a/11540405/ffd3f8792b96/cmh-2024-0222f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33a/11540405/48ba1fdf934c/cmh-2024-0222f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33a/11540405/fe1cd80ee060/cmh-2024-0222f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33a/11540405/458e417d9dad/cmh-2024-0222f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33a/11540405/cd1c348dec7e/cmh-2024-0222f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33a/11540405/5c476f862d3b/cmh-2024-0222f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33a/11540405/9a718fc9f4eb/cmh-2024-0222f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33a/11540405/ffd3f8792b96/cmh-2024-0222f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e33a/11540405/48ba1fdf934c/cmh-2024-0222f7.jpg

相似文献

1
Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury.肝缺血再灌注损伤中分子靶点及治疗干预策略的现状和展望。
Clin Mol Hepatol. 2024 Oct;30(4):585-619. doi: 10.3350/cmh.2024.0222. Epub 2024 Jul 1.
2
MCTR1 inhibits ferroptosis by promoting NRF2 expression to attenuate hepatic ischemia-reperfusion injury.MCTR1 通过促进 NRF2 表达抑制铁死亡,从而减轻肝缺血再灌注损伤。
Am J Physiol Gastrointest Liver Physiol. 2022 Sep 1;323(3):G283-G293. doi: 10.1152/ajpgi.00354.2021. Epub 2022 Aug 2.
3
Targeting NF-κB in Hepatic Ischemia-Reperfusion Alleviation: from Signaling Networks to Therapeutic Targeting.靶向 NF-κB 在肝缺血再灌注缓解中的作用:从信号网络到治疗靶点。
Mol Neurobiol. 2024 Jun;61(6):3409-3426. doi: 10.1007/s12035-023-03787-w. Epub 2023 Nov 22.
4
Remimazolam alleviates hepatic ischemia-reperfusion injury by activating FOXO1/3 signaling : Remimazolam alleviates hepatic ischemia reperfusion injury.瑞马唑仑通过激活FOXO1/3信号通路减轻肝脏缺血再灌注损伤:瑞马唑仑减轻肝脏缺血再灌注损伤。
BMC Gastroenterol. 2025 Apr 22;25(1):283. doi: 10.1186/s12876-025-03820-3.
5
Isoflurane upregulates microRNA-9-3p to protect rats from hepatic ischemia-reperfusion injury through inhibiting fibronectin type III domain containing 3B.异氟醚通过抑制含有 III 型纤维连接蛋白结构域的 3B 来上调 microRNA-9-3p,从而保护大鼠免受肝缺血再灌注损伤。
Cell Cycle. 2021 Aug;20(16):1527-1539. doi: 10.1080/15384101.2021.1947548. Epub 2021 Jul 25.
6
The effect of Ginsenoside Rg1 in hepatic ischemia reperfusion (I/R) injury ameliorates ischemia-reperfusion-induced liver injury by inhibiting apoptosis.人参皂苷 Rg1 对肝缺血再灌注(I/R)损伤的作用通过抑制细胞凋亡减轻缺血再灌注引起的肝损伤。
Biomed Pharmacother. 2020 Sep;129:110398. doi: 10.1016/j.biopha.2020.110398. Epub 2020 Jun 27.
7
The protective role of two oxindole derivatives is mediated by modulating NLRP3/caspase-1 and PI3K/AKT pathways in a preclinical animal model of hepatic ischemia reperfusion injury.两种色胺衍生物通过调节肝缺血再灌注损伤临床前动物模型中的 NLRP3/caspase-1 和 PI3K/AKT 通路发挥保护作用。
Life Sci. 2024 Sep 1;352:122872. doi: 10.1016/j.lfs.2024.122872. Epub 2024 Jun 26.
8
Remifentanil represses oxidative stress to relieve hepatic ischemia/reperfusion injury via regulating BACH1/PRDX1 axis.瑞芬太尼通过调节 BACH1/PRDX1 轴抑制氧化应激来缓解肝缺血/再灌注损伤。
Clin Res Hepatol Gastroenterol. 2024 Oct;48(8):102422. doi: 10.1016/j.clinre.2024.102422. Epub 2024 Jul 16.
9
New progress in roles of nitric oxide during hepatic ischemia reperfusion injury.一氧化氮在肝脏缺血再灌注损伤中的作用新进展。
World J Gastroenterol. 2017 Apr 14;23(14):2505-2510. doi: 10.3748/wjg.v23.i14.2505.
10
Lentinan enhances microbiota-derived isoursodeoxycholic acid levels to alleviate hepatic ischemia-reperfusion injury in mice.香菇多糖可提高微生物群衍生的异熊去氧胆酸水平,以减轻小鼠肝脏缺血再灌注损伤。
Int J Biol Macromol. 2025 Apr;304(Pt 2):140717. doi: 10.1016/j.ijbiomac.2025.140717. Epub 2025 Feb 6.

引用本文的文献

1
CKS2 Mediates Hepatocellular Carcinoma Recurrence After Hepatic Ischemia-Reperfusion Injury Related to M2 Macrophages.CKS2介导与M2巨噬细胞相关的肝缺血再灌注损伤后肝细胞癌复发。
J Inflamm Res. 2025 Aug 27;18:11801-11819. doi: 10.2147/JIR.S543147. eCollection 2025.
2
Feedback Loops Shape Oxidative and Immune Interactions in Hepatic Ischemia-Reperfusion Injury.反馈回路塑造肝脏缺血再灌注损伤中的氧化与免疫相互作用。
Antioxidants (Basel). 2025 Jul 31;14(8):944. doi: 10.3390/antiox14080944.
3
Discovery of a Hepatoprotective Trinor-Sesterterpenoid from the Marine Fungus sp. Against Hepatic Ischemia-Reperfusion Injury.

本文引用的文献

1
Rehmanniae Radix Praeparata aqueous extract improves hepatic ischemia/reperfusion injury by restoring intracellular iron homeostasis.熟地黄水提物通过恢复细胞内铁平衡改善肝缺血/再灌注损伤。
Chin J Nat Med. 2024 Sep;22(9):769-784. doi: 10.1016/S1875-5364(24)60719-3.
2
Cellular and molecular mechanisms of hepatic ischemia-reperfusion injury: The role of oxidative stress and therapeutic approaches.肝缺血再灌注损伤的细胞和分子机制:氧化应激的作用及治疗方法。
Redox Biol. 2024 Sep;75:103258. doi: 10.1016/j.redox.2024.103258. Epub 2024 Jun 27.
3
m 6 A-mediated gluconeogenic enzyme PCK1 upregulation protects against hepatic ischemia-reperfusion injury.
从海洋真菌 中发现一种具有肝保护作用的三降倍半萜类化合物,对抗肝脏缺血再灌注损伤。 (注:原文中“sp.”处信息不完整,可能是某种海洋真菌的具体名称未写全)
Mar Drugs. 2025 Aug 16;23(8):329. doi: 10.3390/md23080329.
4
Study on the Role of Schisandrin B in Ameliorating Hepatic Ischemia-Reperfusion Injury by Modulating Hepatocyte Autophagy.五味子乙素通过调节肝细胞自噬改善肝缺血再灌注损伤的作用研究
Iran J Pharm Res. 2025 Apr 13;24(1):e157033. doi: 10.5812/ijpr-157033. eCollection 2025 Jan-Dec.
5
Knowledge graph and emerging trends in oxidative stress research on hepatic ischemia-reperfusion injury: a bibliometric analysis (1995-2024).肝缺血再灌注损伤氧化应激研究的知识图谱与新趋势:文献计量分析(1995 - 2024年)
Front Pharmacol. 2025 Jun 18;16:1587591. doi: 10.3389/fphar.2025.1587591. eCollection 2025.
6
Identification of PANoptosis related biomarkers to predict hepatic ischemia‒reperfusion injury after liver transplantation.鉴定与PAN细胞焦亡相关的生物标志物以预测肝移植后肝缺血再灌注损伤
Sci Rep. 2025 May 2;15(1):15437. doi: 10.1038/s41598-025-99264-6.
7
Mesenchymal stem cell-derived exosomes: an emerging therapeutic strategy for hepatic ischemia-reperfusion injury.间充质干细胞衍生外泌体:一种用于肝缺血再灌注损伤的新兴治疗策略。
Stem Cell Res Ther. 2025 Apr 14;16(1):178. doi: 10.1186/s13287-025-04302-9.
8
Experimental Liver Surgery for Liver Research: Update, Choice and Translation.用于肝脏研究的实验性肝脏手术:最新进展、选择与转化
J Inflamm Res. 2025 Mar 28;18:4497-4508. doi: 10.2147/JIR.S506737. eCollection 2025.
9
Sinensetin attenuates hepatic ischemia-reperfusion injury through suppressing GRP78/CHOP-mediated endoplasmic reticulum (ER) stress in mice.橙皮素通过抑制GRP78/CHOP介导的内质网(ER)应激减轻小鼠肝脏缺血再灌注损伤。
Front Pharmacol. 2025 Feb 12;16:1519497. doi: 10.3389/fphar.2025.1519497. eCollection 2025.
m6A介导的糖异生酶PCK1上调可保护肝脏免受缺血再灌注损伤。
Hepatology. 2025 Jan 1;81(1):94-110. doi: 10.1097/HEP.0000000000000716. Epub 2023 Dec 12.
4
Gp78 deficiency in hepatocytes alleviates hepatic ischemia-reperfusion injury via suppressing ACSL4-mediated ferroptosis.肝细胞中 Gp78 的缺失通过抑制 ACSL4 介导的铁死亡缓解肝脏缺血再灌注损伤。
Cell Death Dis. 2023 Dec 8;14(12):810. doi: 10.1038/s41419-023-06294-x.
5
Acteoside ameliorates hepatic ischemia-reperfusion injury reversing the senescent fate of liver sinusoidal endothelial cells and restoring compromised sinusoidal networks.毛蕊花糖苷改善肝脏缺血再灌注损伤,逆转肝窦内皮细胞的衰老命运,恢复受损的窦状隙网络。
Int J Biol Sci. 2023 Sep 18;19(15):4967-4988. doi: 10.7150/ijbs.87332. eCollection 2023.
6
FGF18 alleviates hepatic ischemia-reperfusion injury via the USP16-mediated KEAP1/Nrf2 signaling pathway in male mice.FGF18 通过 USP16 介导的 KEAP1/Nrf2 信号通路减轻雄性小鼠的肝缺血再灌注损伤。
Nat Commun. 2023 Sep 30;14(1):6107. doi: 10.1038/s41467-023-41800-x.
7
Chuanxiong Rhizoma extracts prevent cholestatic liver injury by targeting H3K9ac-mediated and cholangiocyte-derived secretory protein PAI-1 and FN.川芎提取物通过靶向H3K9ac介导的胆管细胞衍生分泌蛋白PAI-1和FN预防胆汁淤积性肝损伤。
Chin J Nat Med. 2023 Sep;21(9):694-709. doi: 10.1016/S1875-5364(23)60416-9.
8
5-aminolevulinate and CHIL3/CHI3L1 treatment amid ischemia aids liver metabolism and reduces ischemia-reperfusion injury.5-氨基乙酰丙酸和 CHIL3/CHI3L1 在缺血期间的治疗有助于肝脏代谢并减少缺血再灌注损伤。
Theranostics. 2023 Aug 28;13(14):4802-4820. doi: 10.7150/thno.83163. eCollection 2023.
9
Disulfide-HMGB1 signals through TLR4 and TLR9 to induce inflammatory macrophages capable of innate-adaptive crosstalk in human liver transplantation.二硫键-HMGB1 通过 TLR4 和 TLR9 信号诱导炎症性巨噬细胞,使其能够在人肝移植中进行先天-适应性串扰。
Am J Transplant. 2023 Dec;23(12):1858-1871. doi: 10.1016/j.ajt.2023.08.002. Epub 2023 Aug 9.
10
Alternative splicing of CEACAM1 by hypoxia-inducible factor-1α enhances tolerance to hepatic ischemia in mice and humans.缺氧诱导因子-1α通过可变剪接增强 CEACAM1 对小鼠和人类肝脏缺血的耐受。
Sci Transl Med. 2023 Aug 2;15(707):eadf2059. doi: 10.1126/scitranslmed.adf2059.